Venclexta 10 Mg FC Tablets. Venclexta 50 Mg FC Tablets. Venclexta 100 Mg FC Tablets 10 mg. 50 mg. 100 mg FC tablet
PDF Leaflet Revision Date: 6 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of CLL and AML in adults.
Dosage (summary)
Starting dose 20 mg daily, titrated to 400 mg over 5 weeks.
Onset of Action / Duration
Onset: 6-8 hours, Duration: Not specified.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding.
Key Drug Interactions
- Strong CYP3A inhibitors
- Moderate CYP3A inducers
Contraindications
- Hypersensitivity
- Concomitant use of strong CYP3A inhibitors
Common side effects
- Neutropenia
- Diarrhoea
- Fatigue
- Nausea
Counselling Points
- Take with food
- Hydration to prevent TLS
- Monitor for infections
Serious warnings
- Tumour lysis syndrome
- Serious infections
Important Disclaimer
The Venclexta 10 Mg FC Tablets. Venclexta 50 Mg FC Tablets. Venclexta 100 Mg FC Tablets 10 mg. 50 mg. 100 mg FC tablet professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
